吡格列酮辅助治疗老年2型糖尿病合并高血压的效果及对TNF-α水平的影响

Curative Effect of Pioglitazone in Adjuvant Treatment of Elderly Type 2 Diabetes Patients with Hypertension and Influence on Level of TNF-α

目的观察吡格列酮(Pio)辅助治疗老年2型糖尿病(T2DM)合并高血压(HTN)的临床效果和对TNF-α水平的影响。方法选取2022年4月—2023年5月本院收治的106例T2DM合并HTN患者为研究对象,随机将患者分为研究组与对照组,每组53例。对照组接受常规降血糖联合厄贝沙坦(EPR)治疗,研究组在对照组治疗基础上辅助Pio治疗,观察对比两组的治疗效果。结果治疗前,两组空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)、胰岛素抗糖指数(HOMA-IR)水平比较,差异无统计学意义(P>0.05);治疗后,两组各项水平指标均有所降低,研究组各项血糖指标均低于对照组(P<0.05)。两组血压水平在治疗前无明显差异(P>0.05);治疗后,两组血压水平均有所降低,研究组血压水平显著低于对照组(P<0.05)。治疗前,两组肿瘤坏死因子-α(TNF-α)、脂联素(APN)、血尿素氮(BUN)、血肌酐(SCr)水平无明显差异(P>0.05);治疗后,两组各项指标均有所改善,研究组各项指标改善情况优于对照组(P<0.05)。研究组不良反应发生率与对照组相比无明显差异(P>0.05);研究组并发症发生率低于对照组(P<0.05)。结论在T2DM合并HTN患者的治疗中使用Pio药物进行辅助,治疗效果显著,可达到明显的降糖效果并改善血压水平。同时,该疗法还可降低炎症因子水平,且具有良好的安全性,可降低并发症发生率,具有临床使用价值。

Objective To observe clinical effect and safety of pioglitazone(Pio)in adjuvant treatment of elderly type 2 diabetes mellitus(T2DM)with hypertension(HTN).Methods The paper chose 106 patients in Dapu County Traditional Chinese Medicine Hospital from April 2022 to May 2023 as study subjects,and divided them into study group(53 cases)and control group(53 cases)randomly.Control group was treated with routine hypoglycemic combined with irbesartan(EPR),while study group with Pio treatment based on control group.Curative effect between two groups was comprehensively observed.Results There was no statistically significant difference in fasting blood glucose(FPG),postprandial 2-hour blood glucose(2hPG),glycated hemoglobin(HbA1c),and insulin resistance index(HOMA-IR)between two groups before treatment,(P>0.05).Both groups showed decrease after treatment,thosef of study group were lower than control group(P<0.05).There was no significant difference in blood pressure levels between two groups before treatment(P>0.05),both groups showed decrease after treatment,those of study group were significantly lower than control group(P<0.05).Before treatment,there was no significant difference in tumor necrosis factor-α(TNF-α),adiponectin(APN),blood urea nitrogen(BUN),and blood creatinine(SCr)levels between two groups,(P>0.05).After treatment,all indicators improved,improvement in study group was better than control group(P<0.05).There was no significant difference in incidence of adverse reactions between study group and control group(P>0.05),that in study group was lower than control group(P<0.05).Conclusion Pio drugs can achieve significant effect for patients with T2DM combined with HTN as an adjuvant therapy,can has hypoglycemic effect,improve blood pressure levels,lower levels of inflammatory factors significantly,reduce risks of complications,which has good safety and clinical value.